Ex-4 acts as a high-affinity agonist at the GLP-1 receptor (GLP-1-R) and, as is the case for GLP-1, it is currently under investigation for use in the treatment of diabetes mellitus (Holz & Chepurny, 2003). This evidence concerns the gene GLP1R and diabetes mellitus.